(Q37765830)

22 August 2017

1 reference

title

Biologics in children's autoimmune disorders: efficacy and safety (English)

1 reference

22 August 2017

Luciana Breda

1

1 reference

PubMed ID

20556424

22 August 2017

Marianna Del Torto

series ordinal

2

1 reference

PubMed ID

20556424

22 August 2017

Sara De Sanctis

series ordinal

3

1 reference

PubMed ID

20556424

22 August 2017

Francesco Chiarelli

series ordinal

4

1 reference

22 August 2017

17 June 2010

1 reference

European Journal of Pediatrics

22 August 2017

1 reference

22 August 2017

170

1 reference

22 August 2017

2

1 reference

22 August 2017

157-167

1 reference

https://scigraph.springernature.com/pub.10.1007/s00431-010-1238-z

22 August 2017

0 references

cites work

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Use of biologics in the treatment of childhood rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

CTLA4Ig: bridging the basic immunology with clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Long-term efficacy of biologics in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Pharmacogenetics of etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Targeting interleukin-6 in pediatric rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Medical treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Update on the medical treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Current treatment of juvenile rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Update on biologics in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Antibody engineering to develop new antirheumatic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Comparative overview of safety of the biologics in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Juvenile idiopathic arthritis: current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Clinical value of blocking IL-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Etanercept therapy in children with treatment-resistant uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Biological agents targeting beyond TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Biologic treatments for systemic rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Current management of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Biologic therapies for juvenile arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

“New drugs: Kids come first”: Children should be included in trials of new biological treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-010-1238-Z

When should we use TNF antagonists in children with rheumatic disease?

21 January 2018

1 reference

12 December 2020

Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study

1 reference

12 December 2020

Juvenile idiopathic arthritis: therapies in the 21st century.

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Biologic therapies in juvenile idiopathic arthritis: why and for whom?

1 reference

12 December 2020

Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome

1 reference

12 December 2020

Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters

1 reference

12 December 2020

Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis

1 reference

12 December 2020

Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency

1 reference

12 December 2020

Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel

1 reference

12 December 2020

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis

1 reference

12 December 2020

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody

1 reference

12 December 2020

Abatacept in difficult-to-treat juvenile idiopathic arthritis.

1 reference

12 December 2020

Challenges in the management of juvenile idiopathic arthritis with etanercept

1 reference

12 December 2020

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).

1 reference

12 December 2020

Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina

1 reference

12 December 2020

Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis

1 reference

12 December 2020

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

12 December 2020

Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

10.1007/S00431-010-1238-Z

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xqt3yn2vcnbnbhi2gzi55rcrfi

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_xqt3yn2vcnbnbhi2gzi55rcrfi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xqt3yn2vcnbnbhi2gzi55rcrfi

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/xqt3yn2vcnbnbhi2gzi55rcrfi

30 July 2022